Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 13, 2021 Filed Jan 14, 2021 19:17 UTC |
DARCY THOMAS EDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000899243-21-002094 · doc4.xml · derivative · entry 3 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2021-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. The option originally covered 7,500 shares pre 15-to-1 reverse stock split which became effective on June 15, 2020. F2 · derivative.expiration_date: The Form 4 filed October 4, 2019 incorrectly reported the Expiration Date as October 3, 2029. The correct Expiration Date is June 15, 2021. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 19:17 UTC |
DARCY THOMAS EDirector
|
Exercise / conversionCommon Stock | 500 | $9.59 | $4,793.25 |
DisclosureSEC source: 0000899243-21-002094 · doc4.xml · nonDerivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 00:07 UTC |
Riley Antony AChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0000899243-20-018041 · doc4.xml · derivative · entry 3 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-06-30 F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 23, 2020. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 00:07 UTC |
Riley Antony AChief Financial Officer
|
PurchaseCommon Stock | 2,000 | $14.11 | $28,220.00 |
DisclosureSEC source: 0000899243-20-018041 · doc4.xml · nonDerivative · entry 2 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,065 Read SEC document |
| June 26, 2020 Filed Jul 1, 2020 00:07 UTC |
Riley Antony AChief Financial Officer
|
PurchaseCommon Stock | 4,700 | $14.52 | $68,225.20 |
DisclosureSEC source: 0000899243-20-018041 · doc4.xml · nonDerivative · entry 1 Riley Antony A · CIK 0001339375 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,065 F1 · price: Represents the weighted average share price of an aggregate total of 4,700 shares purchased in the price range of $14.25 to $14.75 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 00:13 UTC |
Wagner Paul A.Director · See Remarks · 10% owner
|
PurchaseCommon Stock | 7,000 | $14.48 | $101,355.80 |
DisclosureSEC source: 0001209191-20-039272 · doc4.xml · nonDerivative · entry 1 Wagner Paul A. · CIK 0001612842 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279,049 F1 · price: Represents the weighted average share price of an aggregate total of 7,000 shares purchased in the price range of $14.1620 to $14.9899 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 15, 2020 17:34 UTC |
DARCY THOMAS EDirector
|
GrantCommon Stock | 1,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036700 · doc4.xml · nonDerivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,858 F1 · shares: On January 9, 2020, the Reporting Person was granted a restricted stock unit award under the Issuer's 2017 Equity Incentive Plan subject to satisfaction of certain performance conditions that were established at the time of the Board's approval of the award on January 9, 2020. The performance conditions were satisfied on June 15, 2020. F2 · shares: Reflects a 15-to-1 reverse stock split which became effective on June 15, 2020. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 00:56 UTC |
Williams Donald AllenDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000899243-20-016938 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the Date of Grant. "Date of Grant" shall mean June 15, 2020. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 00:55 UTC |
Kornfeld StevenDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000899243-20-016937 · doc4.xml · derivative · entry 1 Kornfeld Steven · CIK 0001814653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the Date of Grant. "Date of Grant" shall mean June 15, 2020. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 00:54 UTC |
Eichenfield LawrenceDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000899243-20-016935 · doc4.xml · derivative · entry 1 Eichenfield Lawrence · CIK 0001814892 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the Date of Grant. "Date of Grant" shall mean June 15, 2020. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 00:52 UTC |
Walker Patricia SDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000899243-20-016933 · doc4.xml · derivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the Date of Grant. "Date of Grant" shall mean June 15, 2020. Read SEC document |
| April 14, 2020 Filed Apr 14, 2020 21:00 UTC |
Oliveira Steven Michael10% owner
|
PurchaseCommon Stock | 74,301 | $1.19 | $88,418.19 |
DisclosureSEC source: 0001104659-20-046424 · tm2015887d1_4.xml · nonDerivative · entry 1 Oliveira Steven Michael · CIK 0001358629 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Steven Oliveira Roth IRA Disclosed balance after: 2,873,450 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:17 UTC |
Oliveira Steven Michael10% owner
|
PurchaseCommon Stock | 65,149 | $1.35 | $87,755.70 |
DisclosureSEC source: 0001104659-20-028555 · tv538796_4.xml · nonDerivative · entry 1 Oliveira Steven Michael · CIK 0001358629 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Steven Oliveira Roth IRA Disclosed balance after: 2,799,149 Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 16:32 UTC |
GRUBER HARRY EDirector · President, Science&Innovation
|
GrantCommon Stock | 13,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013879 · doc4.xml · nonDerivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Science&Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,685 F1 · shares: On January 9, 2020, the Reporting Person was granted a restricted stock unit award under the Issuer's 2017 Equity Incentive Plan subject to satisfaction of certain performance conditions that were established at the time of the Board's approval of the award on January 9, 2020 with acceleration of vesting to occur upon the resignation of the Reporting Person. The Reporting Person resigned on February 26, 2020. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 20:27 UTC |
DARCY THOMAS EDirector
|
GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052617 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 20:25 UTC |
GRUBER HARRY EDirector · President, Science&Innovation
|
GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052616 · doc4.xml · derivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Science&Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 4, 2019 20:14 UTC |
Parkinson David RossDirector
|
GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052614 · doc4.xml · derivative · entry 1 Parkinson David Ross · CIK 0001451935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:38 UTC |
FOLETTA MARK GEVP & Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052622 · doc4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:40 UTC |
Jolly DouglasEVP, Research & Pharm Devel
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052623 · doc4.xml · derivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:36 UTC |
Kabbinavar FairoozSVP Clinical Development
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052621 · doc4.xml · derivative · entry 1 Kabbinavar Fairooz · CIK 0001774182 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:34 UTC |
Duvall Martin JDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052620 · doc4.xml · derivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:31 UTC |
Kunkel Lori AnneDirector
|
GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052619 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:29 UTC |
BERGER FRANKLIN MDirector
|
GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052618 · doc4.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:22 UTC |
Hasnain FaheemDirector
|
GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052615 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:11 UTC |
SCHIMMEL PAULDirector
|
GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052613 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:11 UTC |
Hasnain FaheemDirector
|
PurchaseCommon Stock | 250 | $5.15 | $1,287.38 |
DisclosureSEC source: 0001209191-19-033882 · doc4.xml · nonDerivative · entry 3 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010 Disclosed balance after: 245,857 Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:11 UTC |
Hasnain FaheemDirector
|
PurchaseCommon Stock | 3,890 | $5.30 | $20,613.11 |
DisclosureSEC source: 0001209191-19-033882 · doc4.xml · nonDerivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010 Disclosed balance after: 245,607 F2 · price: The weighted average purchase price for the transaction reported was $5.2990, and the range of prices were between $5.29 and $5.30. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:11 UTC |
Hasnain FaheemDirector
|
PurchaseCommon Stock | 38,860 | $4.59 | $178,414.03 |
DisclosureSEC source: 0001209191-19-033882 · doc4.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010 Disclosed balance after: 241,717 F1 · price: The weighted average purchase price for the transaction reported was $4.5912, and the range of prices were between $4.22 and $5.00. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:29 UTC |
DARCY THOMAS EDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033663 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:27 UTC |
Parkinson David RossDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033661 · doc4.xml · derivative · entry 1 Parkinson David Ross · CIK 0001451935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:24 UTC |
Kunkel Lori AnneDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033658 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:22 UTC |
SCHIMMEL PAULDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033657 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:20 UTC |
Hasnain FaheemDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033652 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:16 UTC |
BERGER FRANKLIN MDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033641 · doc4.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| May 28, 2019 Filed May 29, 2019 20:29 UTC |
FOLETTA MARK GEVP & Chief Financial Officer
|
PurchaseCommon Stock | 5,000 | $4.30 | $21,475.00 |
DisclosureSEC source: 0001209191-19-033196 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,042 F1 · price: The weighted average purchase price for the transaction reported was $4.295, and the range of prices were between $4.2245 and $4.3509. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · balance_after: Includes 1,373 shares of Common Stock that were acquired by the Reporting Person on June 8, 2018 pursuant to the Issuer's Employee Stock Purchase Plan and 1,169 shares of Common Stock that were acquired by the Reporting Person on December 10, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 28, 2019 Filed May 29, 2019 20:25 UTC |
Duvall Martin JDirector · Chief Executive Officer
|
PurchaseCommon Stock | 5,000 | $4.34 | $21,678.50 |
DisclosureSEC source: 0001209191-19-033190 · doc4.xml · nonDerivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,605 F1 · balance_after: Includes 1,566 shares of Common Stock that were acquired by the Reporting Person on June 8, 2018 pursuant to the Issuer's Employee Stock Purchase Plan and 968 shares of Common Stock that were acquired by the Reporting Person on December 10, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 24, 2019 Filed May 29, 2019 16:22 UTC |
GRUBER HARRY EDirector · President, Science&Innovation
|
PurchaseCommon Stock | 5,000 | $4.56 | $22,782.50 |
DisclosureSEC source: 0001209191-19-033184 · doc4.xml · nonDerivative · entry 1 GRUBER HARRY E · CIK 0001054917 · Director · President, Science&Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,744 F1 · balance_after: Includes 1,130 shares of Common Stock that were acquired by the Reporting Person on June 8, 2018 pursuant to the Issuer's Employee Stock Purchase Plan and 1,114 shares of Common Stock that were acquired by the Reporting Person on December 10, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:24 UTC |
Kabbinavar FairoozSVP Clinical Development
|
GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001209191-19-024982 · doc4.xml · derivative · entry 1 Kabbinavar Fairooz · CIK 0001774182 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/15/2019; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/15/2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:04 UTC |
Jolly DouglasEVP, Research & Pharm Devel
|
GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016889 · doc4.xml · derivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: 25% of the shares vest on 3/1/2020 amd the balance of the shares vest monthly thereafter. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:06 UTC |
FOLETTA MARK GEVP & Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016902 · doc4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: 25% of the shares vest on 3/1/2020 amd the balance of the shares vest monthly thereafter. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:06 UTC |
Duvall Martin JDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016896 · doc4.xml · derivative · entry 1 Duvall Martin J · CIK 0001313390 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: 25% of the shares vest on 3/1/2020 amd the balance of the shares vest monthly thereafter. Read SEC document |
| January 11, 2019 Filed Feb 26, 2019 21:49 UTC |
Kunkel Lori AnneActing-Chief Medical Officer
|
GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $9.27 | $0.00 |
DisclosureSEC source: 0001209191-19-013586 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Acting-Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-10 F1 · derivative.exercise_date: The stock option vests in full on May 26, 2019. Read SEC document |
| December 10, 2018 Filed May 29, 2019 20:32 UTC |
Jolly DouglasEVP, Research & Pharm Devel
|
GrantCommon Stock | 732 | $8.19 | $5,995.08 |
DisclosureSEC source: 0001209191-19-033202 · doc4.xml · nonDerivative · entry 2 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,478 F2 · kind: This Form 4 is being filed voluntarily to report the acquisition of 732 shares by the Reporting Person on December 10, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:39 UTC |
DARCY THOMAS EDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039406 · doc4.xml · derivative · entry 1 DARCY THOMAS E · CIK 0001126910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:51 UTC |
Parkinson David RossDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039415 · doc4.xml · derivative · entry 1 Parkinson David Ross · CIK 0001451935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:55 UTC |
SCHIMMEL PAULDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039417 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:48 UTC |
Kunkel Lori AnneDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039411 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:43 UTC |
Hasnain FaheemDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039408 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:36 UTC |
BERGER FRANKLIN MDirector
|
GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039405 · doc4.xml · derivative · entry 1 BERGER FRANKLIN M · CIK 0001273885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 08, 2018 Filed May 29, 2019 20:32 UTC |
Jolly DouglasEVP, Research & Pharm Devel
|
GrantCommon Stock | 703 | $8.19 | $5,757.57 |
DisclosureSEC source: 0001209191-19-033202 · doc4.xml · nonDerivative · entry 1 Jolly Douglas · CIK 0001701643 · EVP, Research & Pharm Devel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,746 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 703 shares by the Reporting Person on June 8, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.